Director, ADME External Bioanalysis and Oversight
Eli Lilly and Company
Indianapolis, Indiana
Catherine Brockus, Ph.D. is a Director in the ADME group of Eli Lilly and Company. In her current role, she utilizes more than 35 years of experience in immunoassay design, development, validation and troubleshooting in support of outsourced nonclinical and clinical methods for bioanalysis at numerous CROs. Her experience spans ligand-binding, cell-based and anti-drug antibody methodologies for modalities including therapeutic antibodies, ADCs, gene
and siRNA therapies. Cathy started her career in development of novel applications for abuse drugs, toxins and antibiotic residues for use in US and Asian/Australian laboratories. Following her Ph.D. from Notre Dame studying the genetics and immunogenicity of arboviruses, her experience guided design of electrochemiluminescent assays in several pharma labs in the US. While working at MPI Research (now Charles River Laboratories), she implemented and led the immunology group at the Mattawan, Michigan facility, and acted as a senior study director for large molecule studies. Cathy worked at BMS (NJ) prior to coming to Eli Lilly in 2017, and has supported many successful drug launches achieved by both companies across the past 14 years. She and her husband live near Indianapolis; they have two children and two grandsons.
Disclosure information not submitted.
Leveraging Learnings from Ligand-Binding and LCMS Methodologies for ARC Bioanalysis
Tuesday, July 23, 2024
2:05 PM – 2:35 PM CST